JP2019515931A5 - - Google Patents

Download PDF

Info

Publication number
JP2019515931A5
JP2019515931A5 JP2018556921A JP2018556921A JP2019515931A5 JP 2019515931 A5 JP2019515931 A5 JP 2019515931A5 JP 2018556921 A JP2018556921 A JP 2018556921A JP 2018556921 A JP2018556921 A JP 2018556921A JP 2019515931 A5 JP2019515931 A5 JP 2019515931A5
Authority
JP
Japan
Prior art keywords
isoquinoline
methyl
carboxamide
piperidine
acetamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018556921A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019515931A (ja
JP7023243B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/029797 external-priority patent/WO2017189823A2/en
Publication of JP2019515931A publication Critical patent/JP2019515931A/ja
Publication of JP2019515931A5 publication Critical patent/JP2019515931A5/ja
Application granted granted Critical
Publication of JP7023243B2 publication Critical patent/JP7023243B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018556921A 2016-04-27 2017-04-27 イソキノリン-3イル-カルボキサミドならびにその調製および使用の方法 Active JP7023243B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662328210P 2016-04-27 2016-04-27
US62/328,210 2016-04-27
PCT/US2017/029797 WO2017189823A2 (en) 2016-04-27 2017-04-27 Isoquinolin-3-yl carboxamides and preparation and use thereof

Publications (3)

Publication Number Publication Date
JP2019515931A JP2019515931A (ja) 2019-06-13
JP2019515931A5 true JP2019515931A5 (enExample) 2021-03-25
JP7023243B2 JP7023243B2 (ja) 2022-02-21

Family

ID=60157342

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018556921A Active JP7023243B2 (ja) 2016-04-27 2017-04-27 イソキノリン-3イル-カルボキサミドならびにその調製および使用の方法

Country Status (19)

Country Link
US (5) US10508099B2 (enExample)
EP (2) EP3943086A1 (enExample)
JP (1) JP7023243B2 (enExample)
KR (1) KR102399206B1 (enExample)
CN (1) CN109311819B (enExample)
AR (1) AR108326A1 (enExample)
AU (1) AU2017258187B2 (enExample)
BR (1) BR112018072190A2 (enExample)
CA (1) CA3022044A1 (enExample)
CL (2) CL2018003050A1 (enExample)
CO (1) CO2018012655A2 (enExample)
IL (1) IL262495B (enExample)
MA (1) MA43605B1 (enExample)
MX (1) MX386319B (enExample)
PE (1) PE20190260A1 (enExample)
PH (1) PH12018502259A1 (enExample)
RU (1) RU2018141379A (enExample)
SG (2) SG10201914127PA (enExample)
WO (1) WO2017189823A2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8993555B2 (en) 2012-12-21 2015-03-31 Epizyme, Inc. PRMT5 inhibitors and uses thereof
AR108325A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
AR108326A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
TW201803869A (zh) 2016-04-27 2018-02-01 健生藥品公司 作為RORγT調節劑之6-胺基吡啶-3-基噻唑
WO2017205536A2 (en) * 2016-05-24 2017-11-30 Genentech, Inc. Therapeutic compounds and uses thereof
SG11201908940UA (en) 2017-03-30 2019-10-30 Hoffmann La Roche Isoquinolines as inhibitors of hpk1
AU2018300980A1 (en) 2017-07-12 2020-01-02 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
EP3697781B1 (en) * 2017-10-17 2023-06-07 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4
WO2019079626A1 (en) * 2017-10-19 2019-04-25 Samumed, Llc 6- (HETEROARYL 5-CHAIN) ISOQUINOLIN-3-YL CARBOXAMIDES, THEIR PREPARATION AND THEIR USE
ES3064093T3 (en) 2017-10-20 2026-04-22 Univ Vanderbilt Antagonists of the muscarinic acetylcholine receptor m4
US10653688B2 (en) 2017-10-27 2020-05-19 Samumed, Llc 6-(6-membered heteroaryl and aryl)isoquinolin-3-yl carboxamides and preparation and use thereof
US10413537B2 (en) 2017-10-27 2019-09-17 Samumed, Llc 6-(5-membered heteroaryl)isoquinolin-3-yl-(5-membered heteroaryl) carboxamides and preparation and use thereof
US10703748B2 (en) 2017-10-31 2020-07-07 Samumed, Llc Diazanaphthalen-3-yl carboxamides and preparation and use thereof
CN112334450A (zh) 2018-06-18 2021-02-05 詹森药业有限公司 作为RORγt的调节剂的苯基和吡啶基取代的咪唑
CA3103929A1 (en) 2018-06-18 2019-12-26 Janssen Pharmaceutica Nv Phenyl substituted pyrazoles as modulators of roryt
ES2925473T3 (es) 2018-06-18 2022-10-18 Janssen Pharmaceutica Nv Pirazoles de piridinilo como moduladores de RORyt
EP3806958B1 (en) 2018-06-18 2022-09-07 Janssen Pharmaceutica NV 6-aminopyridin-3-yl pyrazoles as modulators of roryt
TW202019905A (zh) 2018-07-24 2020-06-01 瑞士商赫孚孟拉羅股份公司 異喹啉化合物及其用途
TW202024053A (zh) 2018-10-02 2020-07-01 美商建南德克公司 異喹啉化合物及其用途
US11612606B2 (en) 2018-10-03 2023-03-28 Genentech, Inc. 8-aminoisoquinoline compounds and uses thereof
WO2021004547A1 (en) * 2019-07-11 2021-01-14 Guangdong Newopp Biopharmaceuticals Co., Ltd. Heterocyclic compounds as inhibitors of hpk1
AU2020343737A1 (en) * 2019-09-05 2022-03-31 Lunan Pharmaceutical Group Corporation MAGL inhibitor, preparation method therefor and use thereof
IL299080A (en) * 2020-06-19 2023-02-01 Univ Vanderbilt Arylsulfonyl history and their use as M5 muscarinic acetylcholine receptor inhibitors
CA3195193A1 (en) * 2020-10-29 2022-05-05 Peter H. Fuller N-linked isoquinoline amides as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
EP4294798A1 (en) * 2021-02-19 2023-12-27 Kalvista Pharmaceuticals Limited Factor xiia inhibitors
EP4408427A4 (en) * 2021-10-01 2025-10-15 Merck Sharp & Dohme Llc SYSTEM AND METHOD FOR STATIC AND DYNAMIC MRI COMPENSATION
CA3240400A1 (en) * 2021-12-10 2023-06-15 Prothena Biosciences Limited Methods for treating neurological disorders
TW202506660A (zh) * 2023-04-27 2025-02-16 美商塞普特納公司 Mrgprx2拮抗劑及其使用方法
KR102929140B1 (ko) 2023-05-09 2026-02-24 주식회사 베노바이오 Bet 단백질을 저해하는 신규한 벤조사이오펜 유도체 및 이를 이용한 암 치료용 조성물

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4164559A (en) 1977-09-21 1979-08-14 Cornell Research Foundation, Inc. Collagen drug delivery device
US4474752A (en) 1983-05-16 1984-10-02 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
ES2131463B1 (es) * 1997-04-08 2000-03-01 Lilly Sa Derivados de ciclopropilglicina con propiedades farmaceuticas.
DE19746287A1 (de) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
US6440102B1 (en) 1998-07-23 2002-08-27 Durect Corporation Fluid transfer and diagnostic system for treating the inner ear
DE19853299C2 (de) 1998-11-19 2003-04-03 Thomas Lenarz Katheter zur Applikation von Medikamenten in Flüssigkeitsräumen des menschlichen Innenohrs
US6120484A (en) 1999-02-17 2000-09-19 Silverstein; Herbert Otological implant for delivery of medicament and method of using same
US6967023B1 (en) 2000-01-10 2005-11-22 Foamix, Ltd. Pharmaceutical and cosmetic carrier or composition for topical application
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
US6648873B2 (en) 2001-09-21 2003-11-18 Durect Corp. Aural catheter system including anchor balloon and balloon inflation device
GB0310867D0 (en) 2003-05-12 2003-06-18 Novartis Ag Organic compounds
US7008953B2 (en) 2003-07-30 2006-03-07 Agouron Pharmaceuticals, Inc. 3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
WO2006079055A2 (en) 2005-01-24 2006-07-27 Neurosystec Corporation Apparatus and method for delivering therapeutic and/or other agents to the inner ear and to other tissues
CA2651072A1 (en) 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
KR20100044251A (ko) 2007-08-15 2010-04-29 싸이토키네틱스, 인코포레이티드 특정 화학 물질, 조성물 및 방법
EP2464232B1 (en) * 2009-08-10 2015-10-07 Samumed, LLC Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
EP2464231A4 (en) 2009-08-10 2013-02-06 Samumed Llc INDAZOLE AS WNT / B-CATENINE SIGNALING PATHWASHER AND THERAPEUTIC APPLICATIONS THEREOF
EP2552893B1 (en) 2010-03-31 2014-10-29 Actelion Pharmaceuticals Ltd. Antibacterial isoquinolin-3-ylurea derivatives
TW201307292A (zh) 2010-12-17 2013-02-16 Hoffmann La Roche 經取代之6,6-稠合含氮雜環化合物及其用途
AU2012308570B2 (en) * 2011-09-14 2016-11-10 Samumed, Llc Indazole-3-carboxamides and their use as Wnt/b-catenin signaling pathway inhibitors
WO2013169793A2 (en) * 2012-05-09 2013-11-14 Ipierian, Inc. Methods and compositions for tdp-43 proteinopathies
US9557993B2 (en) 2012-10-23 2017-01-31 Analog Devices Global Processor architecture and method for simplifying programming single instruction, multiple data within a register
PE20170127A1 (es) 2014-03-20 2017-03-30 Samumed Llc Indazol-3-carboxamidas 5-sustituidas y preparacion y uso de las mismas
GB201416754D0 (en) 2014-09-23 2014-11-05 Mission Therapeutics Ltd Novel compounds
AR108325A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
AR108326A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
WO2020006115A1 (en) 2018-06-26 2020-01-02 Betty Tam Methods of treating cancer using a clk inhibitor

Similar Documents

Publication Publication Date Title
RU2018141379A (ru) Изохинолин-3-иловые карбоксамиды и их получение и применение
CN105555783B (zh) 包含杂芳族环‑苄基‑酰胺‑环核心的自分泌运动因子抑制剂
US10214537B2 (en) Bicyclic heteroaryl amine compounds
CN119604501A (zh) 基于嘧啶的调节剂及其用途
AU2005307744C1 (en) 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
KR102616949B1 (ko) 고리형 구조를 갖는 화합물
JP7699595B2 (ja) 統合的ストレス応答経路の調節因子
JP2019519484A5 (enExample)
JP2015529192A5 (enExample)
AU2012334173A1 (en) [1, 2, 3] triazolo [4, 5 -d] pyrimidine derivatives as agonists of the cannabinoid receptor 2
CA2521201A1 (en) Substituted pyrazoles for use in the prophylaxis or treatment of a disease which can be influenced by the binding of the substitued pyrazoles to 5ht receptors
TW201100080A (en) Bridged spiro[2.4]heptane derivatives
JP2018512408A5 (enExample)
JP7643632B2 (ja) Kdm5阻害作用を有する3-アザビシクロ(3.1.0)ヘキサン誘導体およびその医薬用途
US12559462B2 (en) Pyrimidine derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
JP2026505446A (ja) イミダゾトリアジンil-17aモジュレータ及びその使用
JP2017523223A5 (enExample)
CN121464132A (zh) Akt1的共价修饰剂及其用途
JP2021529168A5 (enExample)
WO2021158626A1 (en) Adamts inhibitors, preparation methods and medicinal uses thereof
JP2017516772A5 (enExample)
CN117098753A (zh) 整合应激反应途径的调节剂
JP6169699B2 (ja) 脆弱x症候群、パーキンソン病又は逆流性疾患の治療に有用なジアゼピノン誘導体
JP7834097B2 (ja) 5-ht2aセロトニン受容体に関連する障害を処置するために有用な5-ht2aセロトニン受容体のモジュレーターとしてのイソオキサゾール誘導体
EA051407B1 (ru) Модуляторы пути интегрированного ответа на стресс